| Automated tumor immunophenotyping predicts clinical benefit from anti‐PD‐L1 immunotherapy X Li, J Eastham, JM Giltnane, W Zou, A Zijlstra, E Tabatsky, R Banchereau, ... The Journal of Pathology 263 (2), 190-202, 2024 | 1 | 2024 |
| Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150 A Mang, W Zou, V Rolny, M Reck, D Cigoianu, K Schulze, S Holdenrieder, ... Tumor Biology 46 (s1), S177-S190, 2024 | 1 | 2024 |
| Circulating tumor DNA monitoring on chemo-immunotherapy for risk stratification in advanced non–small cell lung cancer B Pellini, RW Madison, MA Childress, ST Miller, O Gjoerup, J Cheng, ... Clinical Cancer Research 29 (22), 4596-4605, 2023 | 10 | 2023 |
| MA11. 08 IMpower010: exploratory analysis of tumour mutational burden and disease-free survival with adjuvant atezolizumab in NSCLC E Felip, M Srivastava, M Reck, H Wakelee, N Altorki, E Vallieres, ... Journal of Thoracic Oncology 18 (11), S139, 2023 | 2 | 2023 |
| Methods and compositions for non-small cell lung cancer immunotherapy ML Mccleland, S Mocci, W Zou, Y Deng, H Kuriki US Patent App. 18/050,236, 2023 | | 2023 |
| IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care. M Reck, MK Srivastava, HA Wakelee, E Felip, NK Altorki, T Csoszi, ... Journal of Clinical Oncology 41 (16_suppl), 8522-8522, 2023 | 1 | 2023 |
| digital SP263 PD-L1 tumor cell scoring in non-small cell lung cancer achieves comparable outcome prediction to manual pathology scoring H Prizant, J Shamshoian, J Abel, A Beck, L Chambre, S Hennek, ... Cancer Research 83 (7_Supplement), 5358-5358, 2023 | 1 | 2023 |
| A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer ZJF Assaf, W Zou, AD Fine, MA Socinski, A Young, D Lipson, JF Freidin, ... Nature Medicine 29 (4), 859-868, 2023 | 39 | 2023 |
| Tumor dynamic model-based decision support for Phase Ib/II combination studies: a retrospective assessment based on resampling of the Phase III study IMpower150 R Bruno, M Marchand, K Yoshida, P Chan, H Li, W Zou, F Mercier, ... Clinical Cancer Research 29 (6), 1047-1055, 2023 | 10 | 2023 |
| Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase … C Zhou, MK Srivastava, H Xu, E Felip, H Wakelee, N Altorki, M Reck, ... Journal for Immunotherapy of Cancer 11 (10), 2023 | 4 | 2023 |
| Therapeutic and diagnostic methods for cancer D Fabrizio, GM Frampton, P Hegde, M Kowanetz, D Shames, ... US Patent App. 17/686,565, 2022 | 1 | 2022 |
| 1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC) E Felip, M Srivastava, M Reck, H Wakelee, NK Altorki, E Vallieres, ... Immuno-Oncology and Technology 16, 2022 | 10 | 2022 |
| Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy C Julian, RJM Machado, S Girish, P Chanu, D Heinzmann, C Harbron, ... Cancer Reports 5 (10), e1578, 2022 | 9 | 2022 |
| Tumor dynamic model-based decision support for phase Ib immunotherapy combination studies R Bruno, M Marchand, K Yoshida, P Chan, H Li, W Zou, F Mercier, ... Cancer Research 82 (12_Supplement), 5176-5176, 2022 | | 2022 |
| Automated tumor immunophenotyping and response to immunotherapy in non-small cell lung cancer using a spatial statistics approach. D Orlova, X Li, J Eastham-Anderson, W Zou, E Tabatsky, JM Giltnane, ... Journal of Clinical Oncology 40 (16_suppl), 2626-2626, 2022 | 1 | 2022 |
| Therapeutic and diagnostic methods for cancer D Fabrizio, GM Frampton, P Hegde, M Kowanetz, D Shames, ... US Patent 11,300,570, 2022 | 8 | 2022 |
| Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer NS Patil, BY Nabet, S Müller, H Koeppen, W Zou, J Giltnane, A Au-Yeung, ... Cancer cell 40 (3), 289-300. e4, 2022 | 190 | 2022 |
| Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the … HJ West, M McCleland, F Cappuzzo, M Reck, TSK Mok, RM Jotte, ... Journal for Immunotherapy of Cancer 10 (2), 2022 | 82 | 2022 |
| Comparison of SP142 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of atezolizumab in non–small cell lung cancer: results from the randomized OAK trial S Gadgeel, FR Hirsch, K Kerr, F Barlesi, K Park, A Rittmeyer, W Zou, ... Clinical lung cancer 23 (1), 21-33, 2022 | 16 | 2022 |
| 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA … C Zhou, MD Thakur, MK Srivastava, W Zou, H Xu, M Ballinger, E Felip, ... Annals of Oncology 32, S1374, 2021 | 43 | 2021 |
